Faeth Lands Roche Collaboration to Test PIKTOR With Giredestrant in Breast Cancer
FTH sits 41% above its 52-week low of $7.45 on elevated volume (2.1× avg).
Summary
Faeth signed a clinical trial collaboration and supply agreement with Roche to test its lead program PIKTOR alongside Roche's investigational giredestrant in HR+/HER2- advanced breast cancer. Faeth will sponsor and run the Phase 1b/2 study (FTH-PIK-101); Roche supplies the drug, so Faeth takes on the trial cost without paying for the combination agent. The rationale is resistance to endocrine therapy driven by the PI3K/AKT/mTOR pathway, which PIKTOR targets at multiple nodes. This follows the November 9 report of 33% response data for PIKTOR plus paclitaxel in endometrial cancer, and a Big Pharma partner supplying a drug for the breast program adds external validation. First patient in FTH-PIK-101 was dosed in April 2026, with interim data anticipated in 2027.
At the time of this announcement, FTH was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.2M. The 52-week trading range was $7.45 to $42.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.